Skip to content

Evaluating metabolites in patients with major depressive disorder who received mindfulness-based cognitive therapy and healthy controls using short echo MRSI at 7 Tesla.

Yan Li, Angela Jakary, Erin P Gillung, Stuart J. Eisendrath, Sarah J Nelson, Pratik Mukherjee, Tracy Luks

Magma June 2016 DOI: 10.1007/s10334-016-0526-7 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Observational case-control study with pre-post intervention component Peer reviewed
Sample size 26
Population 16 unmedicated patients with major depressive disorder and 10 age- and gender-matched healthy controls
Intervention Mindfulness-based cognitive therapy (MBCT)
Duration 8-week course of MBCT
Topics Depression Meditation
Keywords 7 tesla
Key findings Unmedicated patients with major depressive disorder differed from healthy controls in several brain metabolite ratios at 7 Tesla, including higher total choline-containing compounds/total creatine in the right caudate and lower N-acetyl aspartate/total creatine in the left anterior cingulate cortex. All patients' depression severity decreased after 8 weeks of mindfulness-based cognitive therapy, and improvement was associated with changes in N-acetyl aspartate/total creatine in the left anterior cingulate cortex.

Abstract

Our aim was to evaluate differences in metabolite levels between unmedicated patients with major depressive disorder (MDD) and healthy controls, to assess changes in metabolites in patients after they completed an 8-week course of mindfulness-based cognitive therapy (MBCT), and to exam the correlation between metabolites and depression severity. Sixteen patients with MDD and ten age- and gender-matched healthy controls were studied using 3D short echo-time (20 ms) magnetic resonance spectroscopic imaging (MRSI) at 7 Tesla. Relative metabolite ratios were estimated in five regions of interest corresponding to insula, anterior cingulate cortex (ACC), caudate, putamen, and thalamus. In all cases, MBCT reduced severity of depression. The ratio of total choline-containing compounds/total creatine (tCr) in the right caudate was significantly increased compared to that in healthy controls, while ratios of N-acetyl aspartate (NAA)/tCr in the left ACC, myo-inositol/tCr in the right insula, and glutathione/tCr in the left putamen were significantly decreased. At baseline, the severity of depression was negatively correlated with my-inositol/tCr in the left insula and putamen. The improvement in depression severity was significantly associated with changes in NAA/tCr in the left ACC. This study has successfully evaluated regional differences in metabolites for patients with MDD who received MBCT treatment and in controls using 7 Tesla MRSI.

Comparable studies

Other non-randomized and open-label trials on depression, most cited first.

Study Year Design Participants
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression 2016 Open-label feasibility trial n = 12
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression 2017 Open-label trial n = 20
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression Patients with recurrent depression 2015 Open-label trial n = 17

Citations in the library

Cited by 5

Cites 8

and 3 more in the library

Explore topics